CoChat

Point: If It Is Important to Prevent Type 2 Diabetes, It Is Important to Consider All Proven Therapies Within a Comprehensive Approach

Open access
Gerstein, Hertzel C. · 2007 · Diabetes Care
Cited by 16

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Type 2 diabetes is a common metabolic disease that is defined on the basis of glucose levels above specific thresholds. Individuals with type 2 diabetes are at high risk of blindness, renal failure, amputation, cardiovascular disease, premature death, dementia, and a variety of other chronic diseases and life-threatening events. However, unlike other risk factors for future events (e.g., hyperlipidemia or hypertension), type 2 diabetes is often associated with symptoms and discomfort related to elevated glucose levels that range from fatigue, nocturia, polyuria, and nonspecific aches and pains to dehydration and coma. Moreover, once diabetes is diagnosed, affected individuals incur additional cost and inconvenience related to disease labeling, dietary and lifestyle modification, glucose monitoring, eye assessments, and higher health and life insurance premiums. Several trials have shown that aggressive management of type 2 diabetes can reduce the risk of microvascular disease (1–3), and that multifactorial risk factor interventions can reduce the risk of these and other consequences (4–6). These considerations and epidemiologic evidence that the risk of eye and kidney disease is well below the diagnostic thresholds for diabetes suggest that if glucose levels are prevented from rising past these thresholds, or the rise is delayed, these consequences will also be prevented or delayed. Moreover, evidence that the glucose level is a progressive risk factor for cardiovascular events (i.e., that the risk rises with the glucose level) (7–11) supports the hypothesis that preventing or delaying any rise within the nondiabetic range may reduce the risk of cardiovascular events. Finally, if ongoing clinical trials (12 …

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc06-2147

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

Metadata

Authors
Gerstein, H. C.
Venue
Diabetes Care
Published
2007-02-01
Volume
30
Issue
2
Pages
432-434
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2151948580
Cited by
16
References
16
FWCI
2.40
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.